摘要
目的探究达格列净对2型糖尿病(T2DM)合并颈动脉粥样硬化患者机体中性粒细胞与淋巴细胞比值(NLR)、血小板与淋巴细胞比值(PLR)、C反应蛋白(CRP)、白介素6(IL-6)的影响。方法选取2019年8月~2020年1月郑州大学第二附属医院收治的100例T2DM合并动脉粥样硬化患者作为研究对象,按照随机数字表法将其分为Dap组与Con组,每组各50例。Con组患者采用原降糖方案,Dap组患者采用原降糖方案基础上加用达格列净,治疗20周。比较两组患者治疗前后的NLR、PLR、CRP、IL-6水平。结果治疗前两组患者的NLR、PLR、CRP及IL-6水平比较,差异无统计学意义(P>0.05)。治疗后两组患者的NLR、PLR、CRP及IL-6水平低于治疗前,差异有统计学意义(P<0.05);治疗后Dap组患者的NLR、PLR、CRP及IL-6水平低于Con组,差异有统计学意义(P<0.05)。结论达格列净可降低T2DM合并颈动脉粥样硬化患者NLR、PLR、CRP及IL-6水平,改善机体的低炎症反应状态。
Objective To investigate the effect of Dapagliflozin on the neutrophil to lymphocyte ratio(NLR),platelet to lymphocyte ratio(PLR),C-reactive protein(CRP)and interleukin 6(IL-6)in patients with type 2 diabetes mellitus(T2DM)with carotid atherosclerosis.Methods A total of 100 patients with T2DM complicated with atherosclerosis admitted to the Second Affiliated Hospital of Zhengzhou University from August 2019 to January 2020 were selected as the research objects.They were divided into Dap group and Con group according to the random number method,with 50 cases in each group.The patients in the Con group were treated with proglycemic regimen,and the patients in the Dap group were treated with Dapagliflozin in addition to proglycemic regimen for 20 weeks.The levels of NLR,PLR,CRP and IL-6 in the two groups before and after treatment were compared.Results Before treatment,there were no significant differences in the levels of NLR,PLR,CRP and IL-6 between the two groups(P>0.05).After treatment,the levels of NLR,PLR,CRP and IL-6 in the two groups were lower than those before treatment,and the differences were statistically significant(P<0.05).After treatment,the levels of NLR,PLR,CRP and IL-6 in Dap group were lower than those in Con group,and the differences were statistically significant(P<0.05).Conclusion Dapagliflozin can reduce NLR,PLR,CRP and IL-6 levels in patients with T2DM and arteriosclerosis,and improve the body′s low inflammatory state.
作者
张耀颐
田晨光
ZHANG Yao-yi;TIAN Chen-guang(Department of Endocrine,the Second Affiliated Hospital of Zhengzhou University,He′nan Province,Zhengzhou450014,China)
出处
《中国当代医药》
CAS
2021年第13期119-122,共4页
China Modern Medicine
基金
河南省科技发展计划项目(182102310596)。
